

Network Provider Update

To: Medi-Cal Network Participants
From: Susan Nakahiro, Pharm.D. *Susan Nakahiro*
Director, Pharmacy Benefit and Claims Operations

Subject: Medi-Cal Drug Utilization Review (DUR) Program Educational Articles and Alerts

The Medi-Cal Drug Utilization Review (DUR) Program issues educational articles and alerts with information to improve the quality and cost-effectiveness of prescribing and dispensing practices for Medi-Cal recipients.¹ Blue Shield of California Promise Health Plan will notify you periodically about these articles so that you can apply the information to your practice or facility, as appropriate.

For your convenience, we are including a link to the corresponding update posted by the Medi-Cal DUR Program on their website.

1. [Drug Safety Communication: Stronger Warning Labels for Benzodiazepines](#)
2. [2020 Immunization Updates: Vaccination during COVID-19, Flu, HepA, and Tdap](#)
3. [Clinical Review: 2020 Standards of Care for Treatment of Type 2 Diabetes](#)
4. [Clinical Guideline: Reproductive Health in Rheumatic and Musculoskeletal Diseases](#)
5. [Improving Quality of Care: Update of Risks Associated with Use of Fluoroquinolones](#)
6. [Drug Safety Communication: Withdrawal of All Ranitidine Products](#)
7. [Drug Safety Communication: Mental Health Side Effects from Montelukast](#)
8. [Improving the Quality of Care: Risks Associated with Use of Gabapentin](#)

All Medi-Cal DUR Program Educational Bulletins are available on the Department of Health Care Services (DHCS) [Medi-Cal website](#).

If you have questions about drug utilization for Blue Shield Promise members, please call our Provider Customer Care Department at **(800) 468-9935** from 6 a.m. to 6:30 p.m., Monday through Friday.

¹ These articles are the result of analyses carried out by the Global Medi-Cal DUR Program and are not official policies of the Department of Health Care Services (DHCS).

TBSP11772 (3/21)
Prov_21_024